Market capitalization | $110.54m |
Enterprise Value | $-32.97m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.29 |
EV/Sales (TTM) EV/Sales | -12.26 |
P/S ratio (TTM) P/S ratio | 41.09 |
P/B ratio (TTM) P/B ratio | 0.56 |
Revenue growth (TTM) Revenue growth | 7.92% |
Revenue (TTM) Revenue | $2.69m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Century Therapeutics Inc forecast:
7 Analysts have issued a Century Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.69 2.69 |
8%
8%
|
|
Gross Profit | -11 -11 |
49%
49%
|
|
EBITDA | -119 -119 |
1%
1%
|
EBIT (Operating Income) EBIT | -133 -133 |
4%
4%
|
Net Profit | -130 -130 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Brent Pfeiffenberger |
Employees | 165 |
Founded | 2018 |
Website | www.centurytx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.